API, Inc. Asbestos Settlement Trust

ANNUAL REPORT OF THE TRUSTEE, 2024

API, INC. ASBESTOS SETTLEMENT TRUST

June 2, 2025

TO: Legal Representative, API, Inc. Asbestos Settlement Trust Judge Richard Spicer 874 South Highview Circle Mendota Heights, MN 55118

> Trust Advisor, API, Inc. Asbestos Settlement Trust Michael R. Strom 111 Fourth Avenue North, Apt. 709 Minneapolis, MN 55401

Settlor, API, Inc. Asbestos Settlement Trust API, INC, c/o API GROUP, INC. c/o Chief Executive Officer 1100 Old Highway 8 NW New Brighton, MN 55112

This Annual Report has been prepared by the undersigned as Trustee of the API, Inc. Asbestos Settlement Trust (the "Trust"), pursuant to Sections 2.2 (b), and (c) of the First Amended API, Inc. Asbestos Settlement Trust [Trust] Agreement ("Trust Agreement"). Those sections of the Trust Agreement require the Trustee to prepare and submit an Annual Report containing the Trust's financial statements, auditor's opinion, and summary of type and number of claims to the Trust during the prior year, all as more fully described in those sections of the Trust Agreement.

This Report is the Trustee's Annual Report for 2024.

The Trust has retained the accounting firm of Abdo, LLP, as the Trust's auditors, to prepare the Financial Statements, and to issue a fairness opinion as to those Financial Statements for 2024. Pursuant to that engagement, Abdo, LLP has completed both the Financial Statements, and has issued its Independent Auditor's Report regarding those Statements.

The 2024 Financial Statements are attached as Exhibit A.

The Trust has made payments on Claims during 2024. Payments on Claims made by the Trust in 2024 are:

1) Current Direct Asbestos Claims paid during 2024 as submitted and approved pursuant to Section V4.1 of the Trust's Trust Distribution Procedures ("TDPs")

The summary of payments made to new Current Direct Asbestos Claims in 2024 is attached as Exhibit B.

This Annual Report is submitted solely for the purposes required in the Trust Agreement, and is not intended, nor should it be construed, as legal advice from the Trustee, or the Trust, to Claimants, Claimants' counsel, or others.

This Annual Report has this day been mailed for filing with the Office of the United States Trustee for the District of Minnesota, as described by Section 2(d) of the Trust Agreement, and by Paragraph 43 of the Order Confirming Third Amended Plan of Reorganization of A.P.I., Inc. (November 21, 2005) As Modified at Confirmation, dated December 6, 2005, Case No. BKY 05-30073-GFK.

API, INC. ASBESTOS SETTLEMENT TRUST

Robert D. Brownson

TRUSTEE

Minneapolis, Minnesota

FINANCIAL STATEMENTS

API, INC. ASBESTOS SETTLEMENT TRUST MINNEAPOLIS, MINNESOTA

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

API, Inc. Asbestos Settlement Trust Table of Contents December 31, 2024 and 2023

	Page No.
Independent Auditor's Report	3
Financial Statements	
Statements of Net Claimants' Equity	6
Statements of Changes in Net Claimants' Equity	7
Statements of Cash Flows	8
Notes to the Financial Statements	9



INDEPENDENT AUDITOR'S REPORT

To the Trustee API, Inc. Asbestos Settlement Trust Minneapolis, Minnesota

Opinion

We have audited the accompanying special purpose financial statements of API, Inc. Asbestos Settlement Trust (the Trust), which comprise the statements of net claimants' equity as of December 31, 2024 and 2023, and the related statements of changes in net claimants' equity, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the statements of net claimants' equity of the Trust as of December 31, 2024 and 2023, and the related changes in net claimants' equity and cash flows for the years then ended, in accordance with special-purpose method of accounting described in Note 2.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Trust and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Basis of Accounting

We draw attention to Note 2 of the financial statements, which describes the basis of accounting. The financial statements were prepared on a special-purpose basis of accounting, which is a basis of accounting other than accounting principles generally accepted in the United States of America. The special-purpose basis of accounting has been used in order to present the amount of equity available to current and future claimants. Our opinion is not modified with respect to this matter.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the special-purpose basis of accounting utilized by the Trust described in Note 2. This includes determining that the special-purpose basis of accounting is an acceptable basis for the preparation of the financial statements in the circumstances. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Trust's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are
 appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the
 Trust's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting
 estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Trust's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Restriction on Use

Our report is intended solely for the information and use of the Trustee, the Legal Representative, the Trust Advisor, the beneficiaries of the Trust and the United States Bankruptcy Court for the District of Minnesota and is not intended to be and should not be used by anyone other than these specified parties. This restriction is not intended to limit distribution of this report, which, upon filing with the United States Bankruptcy Court for the District of Minnesota, is a matter of public record.

Abdo

Minneapolis, Minnesota May 22, 2025



FINANCIAL STATEMENTS

API, Inc. Asbestos Settlement Trust Statements of Net Claimants' Equity December 31, 2024 and 2023

	2024	2023
Assets		
Current Assets		
Cash and cash equivalents	\$ 224,808	\$ 513,387
Note receivable, current portion	1,300,000	1,300,000
Investments	4,600,576	3,019,371
Total Current Assets	6,125,384	4,832,758
Other Assets:	1,625,000	2,925,000
Note receivable, net of current portion	1,625,000	2,925,000
Total Other Assets	1,023,000	2,923,000
Total Assets	7,750,384	7,757,758
Liabilities		
Current Liabilities	16,700	23,031
Accounts payable	28,463	197,764
Claims payable	38,900	38,900
Claims processing fees payable	84,063	259,695
Total Current Liabilities	04,003	200,000
Net Claimants' Equity	\$ 7,666,321	\$ 7,498,063
Net claimants' equity, beginning of period	+ . 000 02 	
Net claimants equity, beginning of period		

API, Inc. Asbestos Settlement Trust Statements of Changes in Net Claimants' Equity For the Years Ended December 31, 2024 and 2023

	2024		2023	
Additions:				
Interest income	\$	60,564	\$	3,631
Dividend income		39,003		40,643
Gain on investments		342,970		184,323
Claim processing fees and miscellaneous income		1,000		1,560
Total Additions		443,537		230,157
Deductions:				
Accounting fees		43,291		38,780
Bank charges		242		209
Insurance		6,413		5,900
Investment management fees		26,313		16,875
Legal fees		5,005		
Office expenses		3,255		770
Trustee fees		142,052		138,140
Legal representative fees		64,000		48,000
Foreign taxes		273		34
Total deductions	_	290,844		248,708
Change in net claimants' equity		152,693		(18,551)
Net claimants' equity, beginning of period		7,498,063		6,631,874
Contributions to net claimants' equity		1,074,997		2,149,995
Distributions from net claimants' equity		(1,059,432)		(1,265,255)
Net claimants' equity, end of period	\$	7,666,321	\$	7,498,063

API, Inc. Asbestos Settlement Trust Statements of Cash Flows For the Years Ended December 31, 2024 and 2023

	2024		2023
Cash Inflows Investment income Proceeds from note receivable Proceeds from sale of investments Proceeds from insurance settlement Receipt of claim search fees and miscellaneous income Receipt of claim processing payments Net Cash Inflows	\$ 99,567 1,300,000 2,471,709 1,074,997 1,000 13,500 4,960,773	\$	44,274 1,300,000 314,219 2,149,995 1,560 9,500 3,819,548
Cash Outflows Distributions to claimants Disbursements for trust operating expenses Purchases of investments Refund of claim processing payments Net Cash Outflows	1,228,733 297,091 3,710,028 13,500 5,249,352	_	1,616,440 233,923 1,621,949 9,200 3,481,512
Net Increase (Decrease) in Cash and Cash Equivalents	(288,579)		338,036
Cash and Cash Equivalents, Beginning of Year	 513,387		175,351
Cash and Cash Equivalents, End of Year	\$ 224,808	\$	513,387

Note 1: Description of the Trust

The API, Inc. Asbestos Settlement Trust (the Trust), organized pursuant to Section 524(g) of the United States Bankruptcy Code, was established according to the Third Amended Plan of Reorganization of API, Inc. as modified (the Plan). The Trust was formed to assume all asbestos claims against API, Inc., whether now existing or arising at any time hereafter, and to use the Trust's assets and income to pay holders of allowed asbestos claims in accordance with the Plan and Trust Agreement. The Trust's funding is dedicated solely to the settlement of asbestos health claims and the related costs, as defined in the Plan. The Trust was consummated on February 5, 2007.

The Trust was initially funded with cash, a promissory note from API, Inc., rights to proceeds from asbestos insurance policies and insurance settlement rights.

Note 2: Significant Accounting Policies

Basis of Presentation

The Trust's financial statements are prepared using special-purpose accounting methods that differ from accounting principles generally accepted in the United States of America. The special-purpose accounting methods were adopted in order to present the amount of equity available for payment of current and future claims and operating expenses of the Trust. Since the accompanying special-purpose financial statements are not based on accounting principles generally accepted in the United States of America, accounting treatment by other parties for these same transactions may differ as to timing and amounts. These special-purpose accounting methods are as follows:

- 1) The financial statements are prepared using the accrual basis of accounting.
- 2) The funding received from API, Inc., API Group, Inc., and the insurance companies is added directly to net claimants' equity. The distributions to claimants and litigation expenses incurred in relation to additions to net claimants' equity are deducted directly from net claimants' equity. These funds do not represent income or expenses of the Trust.
- 3) Non-interest bearing notes have not been discounted to present value.
- 4) Costs of non-income producing assets, which will be exhausted during the life of the Trust and are not available for satisfying claims, are expensed as they are incurred. These items include costs of computer hardware and software.
- 5) Investments are recorded at fair value. All interest and dividend income is included in interest and dividend income on the statements of changes in net claimants' equity. Realized and unrealized gains and losses are reflected on the statements of changes in net claimants' equity.
- 6) The Trust does not record a deferred tax asset for net operating loss carryforwards or a deferred tax asset or liability arising from unrealized gains or losses on securities. As of December 31, 2024 and 2023, the net operating loss carryforward available for use in future years was \$3,641,425 and \$3,760,176, respectively.
- 7) Payments for services to be received over an extended period in the future are recorded as expenses when incurred as these amounts are no longer available for the payment of claims.

Cash and Cash Equivalents

The Trust considers unrestricted currency, demand deposits, and certificates of deposit with an initial maturity of three months or less to be cash and cash equivalents.

Note 2: Significant Accounting Policies (Continued)

Fair Value of Investments

The Trust measures its investments at fair value. Fair value is defined as the price at which an asset could be exchanged in a current transaction between knowledgeable and willing parties.

Fixed Assets

The cost of non-income producing assets that will be exhausted during the life of the Trust and are not available for satisfying claims is expensed as incurred. Since inception of the Trust through December 31, 2024, the cost of fixed assets expensed includes website development costs of \$4,003.

Claims Payable

Claims payable on the statements of net claimants' equity reflect claims approved but unpaid as of December 31 of each year.

Estimates

The preparation of financial statements in conformity with the special-purpose accounting methods described above requires Trust management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of additions and deductions to net claimants' equity during the reporting periods. Accordingly, actual results may differ from those estimates.

Date of Trustee Review

In preparing these financial statements, the Trust has evaluated events and transactions for potential recognition or disclosure through May 22, 2025, the date the special-purpose financial statements were available to be issued.

Note 3: Note Receivable

Note receivable as of December 31, 2024 and 2023 consisted of a promissory note from API, Inc. The original face value of the note was \$26,000,000. The note calls for eighty quarterly payments of \$325,000 and is due in full in March 2027. The note bears no interest.

The note is secured by 51 percent of the common shares of API, Inc., a perfected lien against API, Inc. and certain other assets of API, Inc. As part of a reorganization of API, Inc., API, Inc. desired to transfer some of its assets to its wholly owned subsidiary, Tenet Corp. On January 12, 2022, the Trust entered into a pledge agreement with API, Inc. thereby securing the note receivable with all common shares of Tenet Corp and various other assets of Tenet Corp. Tenet Corp also guaranteed the performance obligations of API, Inc. under the original note. The payment terms and the maturity date of the note were not modified.

As of December 31, 2024 and 2023, the note was receivable as follows:

_			2023	
Receivable within one year Receivable in future years	\$	1,300,000 1,625,000	\$ 1,300,000 2,925,000	
=	\$	2,925,000	\$ 4,225,000	

2023

2024

Note 4: Fair Value Measurements

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy are described as follows:

Level 1 - Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Trust has the ability to access.

Level 2 - Inputs to the valuation methodology include:

- Quoted prices for similar assets or liabilities in active markets
- Quoted prices for identical or similar assets or liabilities in inactive markets
- Inputs other than quoted prices that are observable for the asset or liability
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the assets or liability.

Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2024 and 2023.

Government Securities (US Treasury Notes): Valued using quoted process for identical instruments in active markets.

Common Stock: Valued at the closing price reported on the active market in which it is traded.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Trust believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Note 4: Fair Value Measurements (Continued)

The following tables set forth by level, within the fair value hierarchy, the Trust's investments at fair value as of December 31:

	2024			
	Level 1	Level 2	Level 3	Total
Common Stock US Treasury Notes	\$ 2,360,186 2,240,390	\$ - -	\$ -	\$ 2,360,186 2,240,390
Total Investments at Fair Value	\$ 4,600,576	\$ -	\$ -	\$ 4,600,576
		20	23	
	Level 1	Level 2	Level 3	Total
Common Stock US Treasury Notes	\$ 1,724,025 1,295,346	\$ -	\$ -	\$ 1,724,025 \$ 1,295,346
Total Investments at Fair Value	\$ 3,019,371	\$ -	\$ -	\$ 3,019,371
Realized and unrealized gains and losses on investi	ments for the yea	rs ended Decembe	er 31, 2024 and 20	023, are
summarized as follows:				2024
Net realized gain from investments sold Net unrealized gain on investments held				\$ 118,488 224,482
Total additions to net claiments' equity				\$ 342,970
				2023
Net realized gain from investments sold Net unrealized loss on investments held				\$ 27,815 156,508
Total additions to net claiments' equity				\$ 184,323
Note 5: Investment Income				
Investment income consists of:				
			2024	2023
Total interest income Treasury note (premium) discount amortization Interest income			\$ 61,181 (617) 60,564	\$ 3,083 548 3,631
Dividend income			39,003	40,643
Total investment income			\$ 99,567	\$ 44,274

Note 6: Net Claimants' Equity

The contributions to claimants' equity were comprised of contributions from the insurance case settlement of \$1,074,997 and \$2,149,995 for the years ended December 31, 2024 and 2023, respectively.

The distributions from claimants' equity were comprised of distributions to claimants of \$1,059,432 and \$1,265,255 for the years ended December 31, 2024 and 2023, respectively.

The distributions to claimants represent a payment sum percentage of 44 percent of the allowed liquidated value per claimant from the period of January 1, 2022 to July 1, 2023. After July 1, 2023 and through the year ended December 31, 2024, the percentage decreased to 22 percent of the allowed liquidated value per claimant per the Trust Distribution Procedures. The Trust Distribution Procedures allow this percentage to be evaluated at least once per year by the Trustee, the Legal Representative and the Trust Advisor (Advisory Committee). Distributions prior to October 1, 2010 also included enhanced payments for exigent health, extraordinary or extreme hardship claims, if applicable, as determined by the Trustee. As of October 1, 2010, claims could be filed and approved as exigent health, extraordinary or extreme hardship claims, but the enhanced payments are deferred until the Trust is financially capable of making enhanced payments.

Note 7: Income Taxes

For federal income tax purposes, API, Inc. has elected for the qualified assets of the Trust to be taxed as a Designated Settlement Fund (DSF). Income and expenses associated with the DSF are taxed in accordance with Section 468B of the Internal Revenue Code. As of 2020, the federal statutory income tax rate for the DSF is thirty seven percent.

The Advisory Committee believes the Trust is operating in a manner so as to continue to qualify as a Designated Settlement Fund. The Trust recognizes potential interest and penalties pertaining to income tax related issues, if any, as income tax expense. During the years ended December 31, 2024 and 2023, no such interest or penalties were recognized.

The Trust Advisory Committee evaluates all tax positions and makes a determination regarding their likelihood of being upheld under review. For the years ended December 31, 2024 and 2023, the Trust did not have uncertain tax positions for which they recorded a tax liability.

Note 8: Related Party Transactions

The Trust incurred fees of \$206,052 and \$186,140 during the years ended December 31, 2024 and 2023, respectively, from members of the advisory committee in their roles as Trustee, Legal Representative and Trust Advisor. Of these amounts, \$16,113 and \$22,587 are included in accounts payable on the statements of net claimants' equity as of December 31, 2024 and 2023, respectively.

Note 9: Insurance Settlements

Insurance settlement agreements were approved by the courts with seven insurance companies. The settlement agreement with one of the insurance companies, the immediate cash settlement of seven million dollars was paid to the Trust and was nonrefundable. The remainder of the aggregate settlement amount is payable to the Trust upon certain criteria being met. Upon such time that the insurance company reimbursement obligation for all qualified asbestos claims related to the insurance carrier exceeds the original cash settlement amount of seven million dollars, the insurance carrier is obligated to make additional settlement payments to the Trust, up to a maximum of an additional eleven million dollars. As of December 31, 2024, the reimbursement obligation for the insurance carrier was approximately \$6,017,000, which is below the original cash settlement amount. The amount of the potential additional settlement funds is undeterminable at this time and has not been reflected in the financial statements.

Note 10: Insurance Case Settlements

In prior years, various claims had been presented to the Liquidator for Home Insurance Company. During the year ended December 31, 2012, the Trust reached a settlement agreement with the Liquidator for Home Insurance Company. The Trust's claim had been accepted as a Class II claim in the liquidated amount of \$21,500,000. During the years ended December 31, 2024 and 2023, the Trust received \$1,074,997 and \$2,149,995, respectively from their settlement claim. As of December 31, 2024, the Trust has received \$9,675,000 of their approved claim (approximately 45 percent of the settlement amount). As Home Insurance Company is in liquidation, it is anticipated that the Trust will not receive the entire settlement amount. The amount of the potential additional receipts under the settlement is undeterminable at this time and has not been reflected in the financial statements.

Note 11: Concentrations and Credit Risk

The Trust maintains cash balances at various financial institutions. At times during the years ended December 31, 2024 and 2023, the Trust had significant concentrations of credit risk as a result of maintaining its bank accounts with aggregate balances in excess of the federal insurance coverage of \$250,000.

The Trust has a note receivable from API, Inc. This note is secured by 51 percent of the common stock of API, Inc. and certain other assets of API, Inc. As of January 12, 2022, the note receivable was also secured by all common stock of Tenet Corp as well as certain other assets of Tenet Corp, a wholly owned subsidiary of API, Inc. The amount of loss the Trust would occur if API, Inc. should default is not determinable.

The Trust invests in professionally managed portfolios. Such investments are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the Trust's investment account balances and the amounts reported in the special-purpose statements of net claimants' equity and statements of changes in net claimants' equity.

New Claims Paid in 2024

Decedent	State	Disease	Payment	Date Paid
	MN	I - Malignant Mesothelioma	\$117,012.50	3/19/2024
	MN	V - Pleural	\$6,633.00	7/23/2024
	MN	V - Pleural	\$6,633.00	6/4/2024
	MN	I - Malignant Mesothelioma	\$69,575.00	2/27/2024
	MN	IV - Asbestosis	\$12,584.00	6/4/2024
	ND	I - Malignant Mesothelioma	\$25,759.14	7/23/2024
	MN	II - Lung Cancer	\$30,151.00	2/27/2024
	MN	I - Malignant Mesothelioma	\$69,575.00	2/27/2024
Daddario, Patrick	MN	I - Malignant Mesothelioma	\$69,575.00	5/14/2024
Rubesh, Vernie Anton	MN	I - Malignant Mesothelioma	\$69,575.00	3/19/2024
	MN	I - Malignant Mesothelioma	\$69,575.00	5/14/2024
	MN	I - Malignant Mesothelioma	\$69,575.00	7/23/2024
Pennie, Jill	MN	I - Malignant Mesothelioma	\$69,575.00	5/14/2024
Banks, Richard L.	MN	II - Lung Cancer	\$30,151.00	6/4/2024
Bohn, William A.	MN	I - Malignant Mesothelioma	\$69,575.00	6/4/2024
	MN	I - Malignant Mesothelioma	\$69,575.00	7/23/2024
Driste, John Nelson	MN	I - Malignant Mesothelioma	\$69,575.00	10/29/2024
	ND	I - Malignant Mesothelioma	\$25,759.14	12/3/2024
Nalepka, Gerald Leon	MN	I - Malignant Mesothelioma	\$69,575.00	12/3/2024
Dick, Clarence L.	MN	I - Malignant Mesothelioma	\$69,575.00	12/23/2024
	MN	I - Malignant Mesothelioma	\$69,575.00	12/3/2024
	MN	I - Malignant Mesothelioma	\$69,575.00	12/23/2024
		ΤΩΤΔΙ	\$1.228.732.78	
	Daddario, Patrick Rubesh, Vernie Anton Pennie, Jill Banks, Richard L. Bohn, William A. Driste, John Nelson Nalepka, Gerald Leon	MN MN MN MN MN MN MN MN ND MN	MN V - Pleural MN V - Pleural MN V - Pleural MN V - Pleural MN I - Malignant Mesothelioma MN IV - Asbestosis ND I - Malignant Mesothelioma MN II - Lung Cancer MN I - Malignant Mesothelioma MN II - Lung Cancer MN I - Malignant Mesothelioma ND I - Malignant Mesothelioma ND I - Malignant Mesothelioma ND I - Malignant Mesothelioma Nalepka, Gerald Leon MN I - Malignant Mesothelioma Nalepka, Clarence L. MN I - Malignant Mesothelioma ND I - Malignant Mesothelioma	MN